Pharma Mar (OTCMKTS:PHMMF) Upgraded to “Strong-Buy” by Chardan Capital

Chardan Capital upgraded shares of Pharma Mar (OTCMKTS:PHMMF) to a strong-buy rating in a research report sent to investors on Thursday morning, Zacks.com reports.

Pharma Mar Price Performance

OTCMKTS:PHMMF opened at $34.26 on Thursday. The company has a quick ratio of 2.22, a current ratio of 2.63 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average of $32.89 and a 200-day moving average of $33.95. Pharma Mar has a 52 week low of $26.85 and a 52 week high of $46.26.

Pharma Mar Company Profile

Pharma Mar, SA, a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments.